Skip to content
10-Q

Quarterly Report

Voyager Therapeutics, Inc. VYGR

0001104659-26-057097

← back to feed
Filed
May 7, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Apr 30, 2026 60.42M sh
Shares Diluted Q1 2026 · Mar 31, 2026 59.5M sh
Shares Diluted Q1 2026 · Mar 31, 2025 58.35M sh
Capex Q1 2026 · Mar 31, 2026 $14K
Capex Q1 2026 · Mar 31, 2025 $658K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$33.42M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$37.9M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $43.31M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $65.3M
Stockholders Equity Q1 2026 · Mar 31, 2026 $173.67M
Stockholders Equity Q1 2026 · Dec 31, 2025 $196.08M
Stockholders Equity Q1 2026 · Mar 31, 2025 $272.7M
Stockholders Equity Q1 2026 · Dec 31, 2024 $299.76M
Current Liabilities Q1 2026 · Mar 31, 2026 $17.45M
Current Liabilities Q1 2026 · Dec 31, 2025 $26.54M
Total Liabilities Q1 2026 · Mar 31, 2026 $45.66M
Total Liabilities Q1 2026 · Dec 31, 2025 $56.2M
Current Assets Q1 2026 · Mar 31, 2026 $146.98M
Current Assets Q1 2026 · Dec 31, 2025 $202.69M
Total Assets Q1 2026 · Mar 31, 2026 $219.33M
Total Assets Q1 2026 · Dec 31, 2025 $252.28M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.47
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.53
Eps Basic Q1 2026 · Mar 31, 2026 −$0.47
Eps Basic Q1 2026 · Mar 31, 2025 −$0.53
Sga Expense Q1 2026 · Mar 31, 2026 $8.26M
Sga Expense Q1 2026 · Mar 31, 2025 $9.64M
Rd Expense Q1 2026 · Mar 31, 2026 $24.6M
Rd Expense Q1 2026 · Mar 31, 2025 $31.53M
Net Income Q1 2026 · Mar 31, 2026 −$27.94M
Net Income Q1 2026 · Mar 31, 2025 −$31.02M
Operating Income Q1 2026 · Mar 31, 2026 −$30.27M
Operating Income Q1 2026 · Mar 31, 2025 −$34.69M
Revenue Q1 2026 · Mar 31, 2026 $2.59M
Revenue Q1 2026 · Mar 31, 2025 $6.47M